Q. (Qiuwei) Pan, PhD

Qiuwei Abdullah Pan (1981) is a group leader on translational research of viral diseases, aiming at better understanding the epidemiological/clinical features, establishing organoid-based innovative models, studying virus-host interactions and discovering new therapeutics, as well as enhancing preparedness for future epidemic threats.

His research prioritizes, but do not limit himself to, viruses that either primarily or secondarily affect the digestive system. The current focus of his research is mainly on neglected emerging and re-emerging pathogens including hepatitis E virus, hepatitis D virus, monkeypox virus and Oropouche virus, as well as the interactions between viral and non-viral diseases such as fatty liver disease.

In 2022, Dr. Pan founded the Global Hepatitis E Platform (https://www.ghep-hev.com/) to engage multi-stakeholders to advance hepatitis E research, education, public health and patient care, aiming at benefiting both the infected patients and the society at large.

His outstanding contribution to the hepatitis E field has been recognized by the prestigious Emerging Leader Award (2021) from the European Association for the Study of the Liver (EASL). He is a member of the WHO expert group on the “Hepeviridae” viral family (2023) to prioritize pathogens of epidemic and pandemic threat, and a member of the “Post-COVID Network Netherlands”.

His research portfolio has led to important societal impact, new therapeutic discoveries and over 250 publications. As a senior author, his research has been published in scientific journals including Nature Microbiology, Lancet Global Health, Lancet Microbe, Cell Research, PNAS, Nature Communications, Science Advances, Science Signaling, Gastroenterology, Journal of Hepatology, Hepatology.

Selected recent publications (*Correspondence author)

• Ayada I, Li J, Pan Q*.

  Sugar-Sweetened Beverages and Risk of Liver Disease. JAMA. 2023 Dec 12;330(22):2217-2218.

• Li P, Al-Tawfiq JA, Memish ZA, Pan Q^*.

  Preventing drug resistance: combination treatment for mpox. Lancet. 2023 Nov 11;402(10414):1750-1751.

• Li P, Pachis ST, Xu G, Schraauwen R, Incitti R, de Vries AC, Bruno MJ, Peppelenbosch MP, Alam I, Raymond K*, Pan Q*.

  Mpox virus infection and drug treatment modelled in human skin organoids. Nature Microbiology. 2023 Nov;8(11):2067-2079.

• Li Y, Zhang R, Wang Y, Li P, Li Y, Janssen HLA, de Man RA, Peppelenbosch MP, Ou X, Pan Q*.

  Hepatitis E virus infection remodels the mature tRNAome in macrophages to orchestrate NLRP3 inflammasome response. Proc Natl Acad Sci U S A. 2023 Jun 20;120(25):e2304445120.

• Ayada I, van Kleef LA, Zhang H, Liu K, Li P, Abozaid YJ, Lavrijsen M, Janssen HLA, van der Laan LJW, Ghanbari M, Peppelenbosch MP, Zheng MH, de Knegt RJ, Pan Q*.

  Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study. EBioMedicine. 2023 Jan;87:104392.

• Li P, Li Y, Wang Y, Liu J, Lavrijsen M, Li Y, Zhang R, Verstegen MMA, Wang Y, Li TC, Ma Z, Kainov DE, Bruno MJ, de Man RA, van der Laan LJW, Peppelenbosch MP, Pan Q*.

  Recapitulating hepatitis E virus-host interactions and facilitating antiviral drug discovery in human liver-derived organoids. Science Advances. 2022 Jan 21;8(3):eabj5908.

• Ma Z, de Man RA, Kamar N, Pan Q*.

  Chronic hepatitis E: Advancing research and patient care. Journal of Hepatology. 2022 Oct;77(4):1109-1123.

• Li P, Wang Y, Lavrijsen M, Lamers MM, de Vries AC, Rottier RJ, Bruno MJ, Peppelenbosch MP, Haagmans BL, Pan Q*.

  SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. Cell Research. 2022 Mar;32(3):322-324.

• Li P, de Vries AC, Kamar N, Peppelenbosch MP, Pan Q*.

  Monitoring and managing SARS-CoV-2 evolution in immunocompromised populations. Lancet Microbe. 2022 May;3(5):e325-e326.

• Li Y, Yu P, Kessler AL, Shu J, Liu X, Liang Z, Liu J, Li Y, Li P, Wang L, Wang Y, Ma Z, Liu A, Wang L, Bruno MJ, de Man RA, Peppelenbosch MP, Buschow SI, Wang L, Wang Y, Pan Q*.

  Hepatitis E virus infection activates NOD-like receptor family pyrin domain-containing 3 inflammasome antagonizing interferon response but therapeutically targetable. Hepatology. 2022 Jan;75(1):196-212.

• Ji Y, Ma Z, Peppelenbosch MP, Pan Q*.

  Potential association between COVID-19 mortality and health-care resource availability. Lancet Global Health. 2020 Apr;8(4):e480.

• Cao W, Li M, Liu J, Zhang S, Noordam L, Verstegen MMA, Wang L, Ma B, Li S, Wang W, Bolkestein M, Doukas M, Chen K, Ma Z, Bruno M, Sprengers D, Kwekkeboom J, van der Laan LJW, Smits R, Peppelenbosch MP, Pan Q*.

LGR5 marks targetable tumor-initiating cells in mouse liver cancer. Nature Communications. 2020 Apr 23;11(1):1961.

A complete overview of publications can be found on PubMed